Plain-English translation of NCT06891898 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Type 1 Diabetes research guide →This study is following people who use the iLet Bionic Pancreas, an automated device that delivers insulin for type 1 diabetes. Researchers want to understand how well this device works and how safe it is when people use it in real life — not just in a controlled research setting. They'll compare your results to other diabetes patients and to previous research studies.
The medication has been approved for use, but the company needs to continue monitoring it after approval to make sure it stays safe and works well for a large, diverse group of patients over time. This kind of ongoing monitoring helps catch any unexpected problems and confirms that the treatment is helping people manage their diabetes better.
You likely qualify if…
You likely don't qualify if…
You would use the iLet Bionic Pancreas as prescribed by your doctor and share your diabetes data with the researchers. You'll complete surveys at the start of the study, monthly check-ins, and a final survey after the study ends. The research team will collect your blood sugar readings and test results before you start using the device and again at the end to see how your diabetes management has changed.
AI-generated summary from trial data · Oct 3, 2026 · Not medical advice
United States
Sponsor
Beta Bionics, Inc.
Collaborators
The Scripps Research Institute
Enrollment target
~1,875 participants
Started
May 2024
Primary completion
June 2027
Age range
6 Years and older
Last updated on clinicaltrials.gov in September 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Courtney Balliro, BS RN
Beta Bionics
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.